TOKYO -- As Takeda Pharmaceutical readies new drugs expected to generate billions of dollars in revenue, recent staff and R&D cutbacks have raised questions about the future of its pipeline.
Japan's top drugmaker by sales on Friday used its first research and development briefing in five years to spotlight six candidates with prospects to become earnings drivers.
